|Todd Chappell is currently an Entrepreneur-in-Residence (EIR) at BioHealthInnovation, Inc. (BHI) and the National Institutes of Health (NIH). As the first EIR at NIH, he assists the Office of Technology Transfer (OTT) in the evaluation of existing technologies, provides an entrepreneurial perspective to OTT in its evaluation of new licensing proposals from start-up companies, advises OTT on opportunities for new ventures based on NIH/Food & Drug Administration (FDA) technologies, assists with developmental strategies, and mentors scientists to help ensure their research becomes commercially valuable. In his role at BHI, Mr. Chappell oversees the Entrepreneur-in-Residence Program and advises start-up companies in the Maryland area on product development and product strategies.
From 2009 to early 2012, Mr. Chappell was Vice President of Operations for Shape Pharmaceuticals, where he oversaw all day-to-day operations involved in the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Shape sold in April 2014 to Tetralogics, Inc. Prior to Shape, Mr. Chappell was at CombinatoRx Inc. for eight years and served as Director of New Products. In that role, he led at team of analysts overseeing all early-stage product development and strategy across a range of therapeutic areas including inflammation, infectious disease, dermatology, oncology, and ophthalmology.
Mr. Chappell has lead the advancement of four therapeutic programs from assay stage into phase IIa human clinical studies and is a co-inventor on 10 product patents. Mr. Chappell holds a B.S. from University of California at Los Angeles and a M.B.A. from Boston University.